Lunai Bioworks Inc (LNAI) Stock Price, Quote & News

Company Profile

Lunai Bioworks Inc., a pre-clinical stage biotechnology company, provides medicine, diagnostics, and biodefense products the United States and the Netherlands. It operates through three segments, RENB, BioSymetrics, and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer. It also develops an artificial intelligence platform...

Industry: Biotechnology

Sector: Healthcare

Phone: 305 918 1980

Website: www.lunaibioworks.com

Address:

2080 Century Park East, Suite 906, Los Angeles, United States

ReversalTrack Mar. 21 at 6:38 PM

JAGU✅ uranium+rare earth play, Keep this high on watch for next week. JAGU sits right in the middle of: •⚛️ Energy crisis (uranium) •🛰️ Defense tech (rare earths) •🌍 Geopolitical supply shift -The world is entering a resource war and most people still don’t see it Critical minerals uranium and rare earths are now essential for defense energy AI and every advanced system the future depend -Uranium and rare earths are needed in the war and in all things needed in the future, and the US will be flooding billions into South America, exactly where jaguar is.JAGU sitting right where the money is going. US pushing billions into critical minerals in Latin America Argentina becoming a key supply hub And JAGU already has exposure there… Rare earth + uranium + IPO reset = serious setup. $SLND $LNAI $AIRG $AGPU nice list also.

0 · Reply

Perpar Mar. 21 at 1:23 PM

$LNAI I reckon we'll be above $1 here next week, it has great upward potential 🤫✅ #SWMR #SMX

1 · Reply

TeamBullish Mar. 20 at 11:19 PM

REMEMBER!! There’s no such thing as profit being too small. That mindset will hurt you in trading. Base hits are the game. Small wins stacked over time build accounts, protect confidence, and create consistency. Traders usually do not fail because they took profits too early. They fail because they get greedy, ignore clean money, and expect every trade to be a home run. Respect the win, pay yourself, and keep stacking. Let runners be the bonus, not the standard. That is how real growth happens. $AZTR $WNW $LNAI $ANNA $MOBX

2 · Reply

DayTrade_4Life Mar. 20 at 10:46 PM

💰Top Alerts Today 20 March 26: 🔥No better time to Join Us and Learn a Simple Strategy to Make Profits. Learn while the Market is overall down and we have the Lowest Prices of the Year. See Profile. ANNA: 4.30 to 7.84 (82%) AZTR: .26 to .37 (42%) RPGL: .64 to .85 (32%) DRMA: 1.41 to 1.84 (30%) WNW: .14 to .18 (28%) $CURV: 1.50 to 1.90 (26%) $LNAI: .50 to .60 (20%) $MNDR: 1.20 to 1.38 (15%)

0 · Reply

StrykerTactics Mar. 20 at 9:58 PM

$JAGU Going to be a fun next week when we break $2 and start to go higher. Over $2 break can be big. So much more to come imo, today was just a teaser. Great day overall on $IBO $LNKS $DRMA and on $LNAI

0 · Reply

illumantistocks Mar. 20 at 8:24 PM

$LNAI agreed 4pm PST she will be running like fire.. to be very frank over .58 and she can jump up over a dollar easily

0 · Reply

TeamPheonix Mar. 20 at 8:15 PM

Called you $WNW for +576% profits! Now I am calling you very early on $ARBB for a massive run. ARBB is starting its big run and only has 900k share float. Make sure to be early on ARBB if you want to catch the potential 300% move. . $BIAF $LNAI $ARTL

0 · Reply

illumantistocks Mar. 20 at 8:10 PM

$LNAI 1-2 min now for the boom if we get the afternoon pop

1 · Reply

eatsleeptrades Mar. 20 at 8:05 PM

$LNAI smells like a big runner here with this penny stock $ANNA $AZTR $CURV

0 · Reply

illumantistocks Mar. 20 at 7:59 PM

$LNAI

0 · Reply

Lunai Bioworks (NASDAQ: LNAI) Launches National Chemical Defense Consortium Targeting $400M-$1.2B U.S. Countermeasure Programs; 3-Year AI Antidote Development Model

Feb 19, 2026, 8:30 AM EST - 4 weeks ago

Lunai Bioworks (NASDAQ: LNAI) Locks Down Core AI Architecture with U.S. Patent Enabling Precision Disease Subtyping

Feb 13, 2026, 8:31 AM EST - 5 weeks ago

Lunai Bioworks (NASDAQ: LNAI) Highlights Drug Discovery and Biodefense AI Platform on CNBC

Feb 9, 2026, 9:15 AM EST - 5 weeks ago

Lunai Bioworks (NASDAQ: LNAI) Launches AI Oncology Pilot with Clinical-Stage Partner to Analyze Randomized Phase 2 Metastatic Colorectal Cancer Survival Trial Data

Jan 27, 2026, 10:36 AM EST - 7 weeks ago

Lunai Bioworks (NASDAQ: LNAI) Launches Sentinel, an AI Safeguard to Block Large Language Models from Generating Novel Chemical Weapons

Jan 26, 2026, 9:30 AM EST - 7 weeks ago

Lunai Bioworks (NASDAQ: LNAI) Expands NIH-Funded AI Program into Commercial Alcohol Use Disorder Drug Discovery

Dec 18, 2025, 9:00 AM EST - 3 months ago

Lunai Bioworks (NASDAQ: LNAI) Featured in International Business Times as AI Partnership Talks Advance

Dec 9, 2025, 7:45 AM EST - 3 months ago

Lunai Bioworks Identifies Three Parkinson's Subtypes and Prioritized Drug Targets to Accelerate Proof-of-Concept Programs and Strategic Partnerships in a $13B Market

Nov 25, 2025, 7:45 AM EST - 4 months ago

Lunai Bioworks Secures First Licensing LOI Following Landmark Breakthrough Showing Complete Tumor Regression in Humanized Cancer Models

Nov 5, 2025, 9:22 AM EST - 4 months ago

Lunai Bioworks achieves complete regression of both primary and metastatic pancreatic tumors in preclinical humanized models, marking a breakthrough in allogeneic cancer immunotherapy

Oct 30, 2025, 9:32 AM EDT - 5 months ago

Lunai Bioworks Harnesses AI and Zebrafish Data to Advance Early Detection of Neurotoxic Compounds

Oct 16, 2025, 9:45 AM EDT - 5 months ago

Landmark Study Identifies Prognostic Biomarkers in Duchenne Muscular Dystrophy Using Large-Scale Serum Proteomics

Oct 16, 2025, 9:15 AM EDT - 5 months ago

Lunai Bioworks Regains Compliance with Nasdaq Minimum Bid Price Requirement

Oct 6, 2025, 9:15 AM EDT - 5 months ago

Lunai Bioworks Launches AI-Powered Alzheimer's Disease Program, Expanding Neurodegenerative Pipeline

Sep 30, 2025, 9:15 AM EDT - 6 months ago

Lunai Bioworks Unveils New Corporate Identity, Streamlined Capital Structure, and Strategic Focus on AI-Powered Therapeutics and Biodefense

Sep 25, 2025, 8:30 AM EDT - 6 months ago

Lunai Bioworks Advances Biomarker Discovery Preclinical Program in Parkinson's Disease, Positioning for Strategic Pharma Partnerships

Sep 24, 2025, 4:50 PM EDT - 6 months ago

Lunai Bioworks, Inc. to Effect 10:1 Reverse Stock Split

Sep 11, 2025, 7:00 AM EDT - 6 months ago

Lunai Bioworks subsidiary BioSymetrics and Brigham and Women's Hospital Awarded NIH STTR Grant to Develop AI-Powered Platform for Alcohol Use Disorder Therapeutics

Sep 9, 2025, 9:12 AM EDT - 6 months ago

Top 3 Health Care Stocks You'll Regret Missing In Q3

SMMT

Sep 9, 2025, 8:47 AM EDT - 6 months ago

Lunai Bioworks Inc. Unveils Transformer Platform to Secure Generative AI and Accelerate Drug Discovery

Sep 8, 2025, 8:50 AM EDT - 6 months ago

Lunai Bioworks Strengthens European Strategy Through Restructuring

Sep 4, 2025, 10:05 AM EDT - 7 months ago

Lunai Bioworks Inc. Retains American Defense International

Aug 27, 2025, 9:45 AM EDT - 7 months ago

Renovaro Inc. Announces Corporate Name Change to Lunai Bioworks, Inc., Reflecting Strategic Focus on AI-Driven Biodefense, Drug Discovery and Advanced Diagnostics

Aug 8, 2025, 10:45 AM EDT - 8 months ago

Renovaro Inc. (NASDAQ: RENB) Mentioned in RealClearDefense Article on AI and Biodefense Risks

Jul 28, 2025, 10:38 AM EDT - 8 months ago

Renovaro Secures Key AI Patents, Strengthening Market Position in $20B Biomedical AI Sector

Jul 17, 2025, 9:15 AM EDT - 8 months ago

Peer-Reviewed Study Validates Renovaro's Genetically Engineered Dendritic Cell Therapy with Potent Anti-Tumor Efficacy

Jul 9, 2025, 8:00 AM EDT - 9 months ago

Renovaro Strengthens Balance Sheet Through Debt Conversion and Advances AI-Driven Initiatives

Jun 30, 2025, 9:21 AM EDT - 9 months ago

Renovaro Launches AI-Based Neurotoxin Countermeasure Initiative Addressing Emerging National Security Needs

Jun 3, 2025, 9:15 AM EDT - 10 months ago

Renovaro Secures Key U.S. Patent to Strengthen AI-Driven Drug Discovery and Diagnostics Platform

May 22, 2025, 3:12 PM EDT - 10 months ago

UPDATE - Renovaro Inc. Announces Expedited Trial for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology

May 22, 2025, 11:05 AM EDT - 10 months ago

Renovaro Inc. Announces Expedited Trail for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology

May 14, 2025, 9:15 AM EDT - 11 months ago

Renovaro Launches Augusta, an AI-Powered Precision Neurology Platform

May 13, 2025, 9:15 AM EDT - 11 months ago

Renovaro and Amsterdam University Medical Center Announce Exclusive Collaboration to Advance Blood Platelet RNA Diagnostics

Apr 22, 2025, 9:20 AM EDT - 11 months ago

Renovaro Secures High-Powered Computing from Nebul Through a Partnership to Accelerate Next-Generation Biomarker Discovery and Diagnostic Programs

Apr 9, 2025, 9:25 AM EDT - 1 year ago

Renovaro and BioSymetrics Close Merger to Accelerate AI-Driven Biomarker Discovery and Precision Medicine

Apr 4, 2025, 9:40 AM EDT - 1 year ago

Renovaro Provides Update to Definitive Agreement with Predictive Oncology

Mar 3, 2025, 9:15 AM EST - 1 year ago

Renovaro Completes First Milestone Payment to Finalize Definitive Agreement with Predictive Oncology

Feb 26, 2025, 1:25 PM EST - 1 year ago

Renovaro and BioSymetrics Announce Definitive Merger Agreement to Advance AI-Driven Biomarker Discovery and Precision Medicine

Feb 26, 2025, 9:15 AM EST - 1 year ago

Renovaro Announces $15 million in Equity Committed

Jan 7, 2025, 6:51 PM EST - 1 year ago

PREDICTIVE ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Predictive Oncology Inc. - POAI

AGPU

Jan 7, 2025, 9:15 AM EST - 1 year ago

Renovaro Appoints Nathen Fuentes as Chief Financial Officer

Jan 7, 2025, 9:15 AM EST - 1 year ago

Renovaro Issues Shareholder Letter and Provides Corporate Update

Jan 6, 2025, 9:15 AM EST - 1 year ago

Renovaro to Acquire Predictive Oncology in All-Stock Transaction

Dec 30, 2024, 9:00 AM EST - 1 year ago

Renovaro Inc. Appoints Maurice van Tilburg to Lead GEDi Cube BV

Dec 23, 2024, 9:00 AM EST - 1 year ago

RenovaroCube Receives Approval of Lumina Project by the Eurostars Funding Program

Dec 20, 2024, 3:40 PM EST - 1 year ago

Renovaro Regains Compliance with NASDAQ Listing Requirement

Dec 20, 2024, 9:00 AM EST - 1 year ago

Renovaro Enters into a Strategic Collaboration with Nebul to Advance a Paradigm Shift for Early Disease Detection

Oct 17, 2024, 9:15 AM EDT - 1 year ago

RenovaroCube Presents Novel Insights on Non-Invasive Cancer Diagnostics Using Oxford Nanopore Sequencing

Oct 16, 2024, 9:28 AM EDT - 1 year ago

Renovaro Announces Strategic Restructuring and Leadership Transition

Sep 13, 2024, 9:00 AM EDT - 1 year ago

RenovaroCube to Present Cutting-Edge Cancer Diagnostics Research at European Society for Medical Oncology Congress

ReversalTrack Mar. 21 at 6:38 PM

0 · Reply

Perpar Mar. 21 at 1:23 PM

$LNAI I reckon we'll be above $1 here next week, it has great upward potential 🤫✅ #SWMR #SMX

1 · Reply

TeamBullish Mar. 20 at 11:19 PM

2 · Reply

DayTrade_4Life Mar. 20 at 10:46 PM

0 · Reply

StrykerTactics Mar. 20 at 9:58 PM

0 · Reply

illumantistocks Mar. 20 at 8:24 PM

$LNAI agreed 4pm PST she will be running like fire.. to be very frank over .58 and she can jump up over a dollar easily

0 · Reply

TeamPheonix Mar. 20 at 8:15 PM

0 · Reply

illumantistocks Mar. 20 at 8:10 PM

$LNAI 1-2 min now for the boom if we get the afternoon pop

1 · Reply

eatsleeptrades Mar. 20 at 8:05 PM

$LNAI smells like a big runner here with this penny stock $ANNA $AZTR $CURV

0 · Reply

illumantistocks Mar. 20 at 7:59 PM

$LNAI

0 · Reply

AltradoLinguini Mar. 20 at 7:58 PM

$LNAI 🟩🟩🟩

0 · Reply

topstockalerts Mar. 20 at 7:55 PM

$LNAI early cycle name, not fully crowded yet. These are the ones that can sneak a run before they get obvious.

0 · Reply

Wetwilly69 Mar. 20 at 7:52 PM

$LNAI push the .60

0 · Reply

AnonymousNYS Mar. 20 at 7:46 PM

$LNAI Co will take their 200M parting gift from a major. No way, will the majors let a little co like this have so much influence on reducing trials times from 3yrs to 1 yr......yea...Parting gift incomming. 5-10pps.

1 · Reply

AltradoLinguini Mar. 20 at 7:41 PM

$LNAI Gonna run, only question is if today’s the day it melts our faces off. Either way, money printer bout to print 🟩🟩🟩

0 · Reply

eatsleeptrades Mar. 20 at 7:30 PM

$LNAI second wind

0 · Reply

illumantistocks Mar. 20 at 7:29 PM

$LNAI i believe this is more relistic yes the only thing i would add is we will test .58 again and if we go .60 we could see a dollar she has more packed in that what you think

0 · Reply

barleycorn Mar. 20 at 7:22 PM

$LNAI back next week for another try at that $1. prediction

1 · Reply

AshCash93 Mar. 20 at 7:21 PM

$LNAI price action today has a a lot to do with people selling who bought on Tuesday when this surged. Volume was insane that day, and since it didn’t hold gains into Wednesday and Thursday they’re trying to get out at breakeven first chance they get. I don’t expect a full recovery to $0.70+ for at least another few trading sessions. Hoping she closes above $0.50 and gives some strength signals into next week.

0 · Reply

AltradoLinguini Mar. 20 at 7:16 PM

$LNAI Definitely not over yet IMO- it’s already jumping around +/- 6% and clearly wants to move up. Bull whales positioning their bulk buy quantities & limit prices now so a spike is close enough to 4pm close that it won’t get cut off by halts… NFA, but I think this thing is going to run hard into AH 🟩🟩🟩 I make no predictions about next week, but today? There’s still a lot of cheddar 🧀 to be made :) GLTA! 🍀🍀🍀

0 · Reply

illumantistocks Mar. 20 at 7:07 PM

$LNAI its on folks we go parabolic AH !! get in before to late

1 · Reply

eatsleeptrades Mar. 20 at 7:07 PM

$LNAI she’s still not done.

0 · Reply

Market Cap	13.47M
Revenue (ttm)	0.00
Net Income (ttm)	-178.01M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	80,784,797
Avg Vol	14,079,349
Day's Range	N/A - N/A
Shares Out	24.19M
Stochastic %K	54%
Beta	0.56
Analysts	Strong Buy
Price Target	N/A